Abstracts tagged "anti-TNF therapy and biomarkers"

Abstract Number: 575 • 2012 ACR/ARHP Annual Meeting
Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen², Morten Asser Karsdal³, Efstathios Vassiliadis⁴, Stephanie Wichuk⁵, Claus Christiansen⁶ and Walter P. Maksymowych⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶CCBR, Ballerup, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Chronic inflammatory diseases such as Ankylosing Spondylitis (AS) are diverse and therefore hard to clearly diagnose and treat. Conventional biomarkers for AS, as CRP…
Abstract Number: 538 • 2012 ACR/ARHP Annual Meeting
Association Between Biomarkers (Metalloproteinase-3, Dikkopf-1 and Sclerostin) with Disease Activity and Prediction of Anti-TNFá Therapy Response in Patients with Ankylosing Spondylitis
Victoria Navarro-Compán¹, Rafael Ariza², Rufino Mondéjar-García³, Virginia Moreira-Navarrete⁴, Enrique Melguizo-Madrid³, Blanca Hernández-Cruz⁴, Concepción González-Rodríguez³ and Federico Navarro-Sarabia⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, University Hospital Virgen Macarena.Sevilla, Sevilla, Spain, ³Biochemistry, University Hospital Virgen Macarena, Sevilla, Spain, ⁴Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁵Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain
Background/Purpose: Better objectives measures for evaluating disease activity and anti-TNFα response in patients with ankylosing spondylitis (AS) are needed. MMP-3 seems to be the most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].